Skip to main content
AKTS
NASDAQ Life Sciences

EcoR1 Capital and Director Oleg Nodelman Disclose 9.1% Stake in Aktis Oncology

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$19.475
Mkt Cap
$1.023B
52W Low
$19.02
52W High
$29.16
52W Position info
2.4% above low
Off High info
33% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

AKTS is trading near its 52-week low of $19.02 (2.4% above the low) on light trading volume (0.1× avg).

Summary

EcoR1 Capital and director Oleg Nodelman have reported a 9.1% beneficial ownership in Aktis Oncology, signaling a significant investment and confidence in the company's prospects.


Key Events · Ownership and Investor Activity · AKTS

  • Significant Ownership Disclosure

    EcoR1 Capital, LLC and its manager Oleg Nodelman, a director of Aktis Oncology, have filed an initial Schedule 13D, disclosing a 9.1% beneficial ownership stake in the company.

  • Substantial Investment Value

    The reported stake, totaling 4,862,335 shares, represents a significant investment valued at approximately $94.69 million based on the current stock price.

  • Investment Rationale

    The reporting persons acquired the securities for investment purposes, believing Aktis Oncology's shares represent an attractive opportunity.

  • Director's Conviction

    Oleg Nodelman's dual role as a director and manager of the investing entity adds weight to the conviction behind this substantial stake, especially as the stock trades near its 52-week low.


Analysis · AKTS · Life Sciences

EcoR1 Capital, a prominent life sciences investment firm, along with its manager Oleg Nodelman, who also serves as a director of Aktis Oncology, has disclosed a significant 9.1% beneficial ownership stake. This initial Schedule 13D filing indicates a substantial long-term investment, with the reporting persons stating their belief that the company's securities represent an attractive investment opportunity. The timing of this disclosure, with the stock trading near its 52-week low, suggests strong conviction from a key institutional investor and insider.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AKTS was trading at $19.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $19.02 to $29.16. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AKTS - Latest Insights

AKTS
Nov 12, 2026, 8:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $17.04
Real-time Price: $16.16 info
Change: -$0.880 (-5%) info
Market Cap: $898.811M info
AKTS
Oct 01, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $19.30
Real-time Price: $16.16 info
Change: -$3.14 (-16%) info
Market Cap: $898.811M info
AKTS
Jul 10, 2026, 6:11 AM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $28.50
Real-time Price: $16.16 info
Change: -$12.34 (-43%) info
Market Cap: $898.811M info
AKTS
May 21, 2026, 5:21 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $19.12
Real-time Price: $16.16 info
Change: -$2.96 (-15%) info
Market Cap: $898.811M info
AKTS
May 11, 2026, 4:06 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $18.27
Real-time Price: $16.16 info
Change: -$2.11 (-12%) info
Market Cap: $898.811M info